OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).

OBM Neurobiology publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 7.5 weeks; Submission to Acceptance: 15.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Natural Products and Their Bioactive Compounds for Treatment of Neurodegenerative Brain Disorder

Submission Deadline: October 30, 2024 (Open) Submit Now

Guest Editor

Dr. Talha Bin Emran, Associate Professor

Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, 4381, Bangladesh

Website | E-Mail

Research interests: Natural Product Chemistry, Alternative Medicine, Phytochemistry, Bioinformatics, Immunology, Vaccinology.

About This Topic

For many years, natural products have been recognized as an important source of therapeutic compounds. In particular, the use of plant-derived active substances for use in neurodegenerative brain disorders natural products has been in use since the start of modern medicine. Nature's medicinal properties have historically correlated with their chemical, biochemical, and synthetic activities. These natural products' unique properties are thus being harnessed by modern scientific advancement in molecular and cellular biology as well as analytical chemistry and pharmacology in order to take full advantage of these products' chemical and structural diversity and biodiversity as well as the potential therapeutic effects of these products. The rearrangement of chemical entities or structural isomers of naturally existing products is often used in drug design units to develop novel compounds that can be used in clinical trials.

The discovery of new pharmaceutical drug candidates may be aided by an integrated method that combines modern genetic sequencing with biosynthetic pathway management. Understanding how structural confirmations or functionality relate to molecular activity is crucial to the success of natural products in previous and current medication research. Nature continues to produce biological diversity, which is vital to target, especially given the lack of results from combinatorial techniques. If the environment continues to yield untapped resources, we may be able to discover novel anti-infective agents.


  1. Role of medicinal plants in neurodegenerative brain disorders
  2. Bioactive natural products as anti-neurodegenerative agents
  3. Phytochemical analysis, characterization, and pharmacological investigation
  4. Structure identification through GC–MS, NMR, IR, HPLC, and HPTLC
  5. Extraction and isolation of bioactive compounds
  6. Bioactive compounds and functional properties
  7. Immunomodulatory properties of medicinal plants
  8. Role of medicinal plants in neurodegenerative diseases
  9. Computer-aided drug design
  10. Discovery of new pharmaceutical drug candidates
  11. Development of new technologies has revolutionized the screening of natural products
  12. Molecular modeling studies

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (neurobiology@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!


Open Access Review

Red Algae Compounds: Potential Neuroprotective Agents for Neurodegenerative Disorders

Received: 06 March 2024;  Published: 10 May 2024;  doi: 10.21926/obm.neurobiol.2402223


This review explores the potential of compounds derived from red algae (Rhodophyta) as promising neuroprotective agents for treating neurodegenerative disorders. Red algae, abundant in marine environments, contain bioactive compounds with diverse chemical structures and functionalities. Sulfated polysaccharides, primarily agar and carrageenans [...]
Open Access Review

Scope of Nanomaterials in Treating Neurological Disorders

Received: 08 November 2023;  Published: 11 January 2024;  doi: 10.21926/obm.neurobiol.2401208


In the last decade, development in nanotechnology has been used intensively. By studying nanotechnology and nanomaterials, we can generate excellent responses in healthcare related to neurological disorders. It also includes easy diagnosis of diseases in their early stages, delivery of genes, and many more. Neurological disorders are one of [...]
Open Access Original Research

Neuroprotective Effects and Cognitive Enhancement of Allomargaritarine in 5xFAD Alzheimer's Disease Mice Model

Received: 23 August 2023;  Published: 09 January 2024;  doi: 10.21926/obm.neurobiol.2401207


Here, we report the results of an investigation of the neuroprotective effects of securinine with tryptamine conjugate-allomargaritarine (2b), previously selected as the leading compound among a wide range of natural derivatives. 2b was synthesized from securinine using various Lewis acids as catalysts. In addition to the antioxidant and c [...]
Open Access Original Research

Effects of Ficus Platyphylla-Induced Hypothermia on Long-term Functional Recovery after Ischaemic Stroke

Received: 19 October 2023;  Published: 05 December 2023;  doi: 10.21926/obm.neurobiol.2304200


A stroke is a cerebrovascular disease that results from a blockage in the blood supply to part of the brain or a burst blood vessel in the brain. It is the second leading cause of death worldwide, with an annual mortality rate of about 5.5 million. Antithrombotic therapies have failed to provide a cure for this debilitating cerebrovascular [...]
Open Access Original Research

Evaluation of Bioactive Compounds Obtained from Ginkgo Biloba Against Crystal Structure of Myelin Oligodendrocyte Glycoprotein (MOG)

Received: 07 July 2023;  Published: 09 October 2023;  doi: 10.21926/obm.neurobiol.2304186


Multiple Sclerosis (MS) spreads rapidly across the globe, causing almost 2.8 million cases worldwide. Many drugs and inhibitors, such as dronabinol and nabilone, have been used to treat MS, but there is no effective treatment for MS till now as these medications can cause severe side effects. So, we tested different compounds from [...]